For the latest COVID information Click Here.
Updated December 2023
Romosozumab (brand name Evenity®) is a medication used to treat osteoporosis (bone loss). Osteoporosis is a common condition which causes bones to become fragile and brittle so that they break (fracture) more easily. Fractures are painful and restrict a person’s ability to carry out their normal daily tasks. Romosozumab reduces the risk of a broken bone or fracture.
You will likely not feel any different after taking romosozumab. Taking romosozumab can help to increase bone strength and reduce the chance of fracture.
If you stop or delay your romosozumab treatment, your disease may get worse. Keep taking your treatment, unless advised by your rheumatologist to stop or unless serious side effects occur (see Side effects).
If you stop romosozumab for any reason you must contact your rheumatologist. Failure to do so may mean that your treatment may no longer be funded.
Medications like romosozumab are very expensive and are funded by Medicare. Certain conditions must be met to receive it.
Romosozumab will only be given if your osteoporosis is severe (very low bone mineral density) and you are at high risk of a fracture (i.e. have already had a fracture).
A blood test is needed before starting your treatment. Regular blood tests are not required, however may be requested by your doctor if you suffer any side effects.
Romosozumab should be given as two subcutaneous injections every month. If you miss an injection: have the next injection as soon as you remember, then subsequent injection a month later and then continue as you normally would with monthly injections. Do not inject a double dose to make up for a missed dose. If you have missed more than one dose or are not sure what to do, check with your doctor or pharmacist.
Romosozumab is a solution for injection that comes in a pre-filled syringe or autoinjector ‘pen’ device. Each injection contains 105mg of romosozumab. For osteoporosis fracture risk reduction, the usual dose of romosozumab is 210mg (two pens at a time) injected each month for 12 months. The benefit of romosozumab past 12 months is not known. It is common to change to an anti-resorptive treatment such as denosumab (Prolia®) or zoledronic acid (Aclasta®) after the 12 month course of romosozumab to ‘lock in’ the improvement in bone strength.
Romosozumab may be used alone or with other arthritis medications including:
Romosozumab should not be used at the same time as other bone strengthening medications such as alendronate (Fosamax®, risedronate (Apotex®), zoledronic acid (Aclasta® or denosumab (Prolia®).
Romosozumab is generally very well tolerated, but everyone is different and you might experience side effects with your treatment. Tell your doctor if you notice side effects that you think are caused by this medication. Many side effects disappear when romosozumab treatment is stopped.
Most common side effects
Hypocalcaemia (low calcium)
Myocardial infarction (heart attack) and stroke
Osteonecrosis of the jaw
Atypical femur fracture
Vaccines
Surgery
Use in pregnancy and when breastfeeding